ADAR1 Capital Management LLC Has $131,000 Stock Holdings in CASI Pharmaceuticals, Inc. (NASDAQ:CASI)

Posted by Floyd Graber on Apr 8th, 2025

ADAR1 Capital Management LLC trimmed its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) by 28.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,320 shares of the biotechnology company’s stock after selling 18,515 shares during the quarter. ADAR1 Capital Management LLC owned 0.30% of CASI Pharmaceuticals worth $131,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on CASI Pharmaceuticals in a report on Friday. They set a “hold” rating on the stock.

Check Out Our Latest Report on CASI

CASI Pharmaceuticals Price Performance

Shares of CASI opened at $2.01 on Tuesday. The stock has a 50 day simple moving average of $2.32 and a 200 day simple moving average of $3.65. CASI Pharmaceuticals, Inc. has a 52-week low of $1.90 and a 52-week high of $7.67. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.32 and a current ratio of 3.20. The firm has a market capitalization of $24.72 million, a PE ratio of -0.90 and a beta of 0.66.

CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.19). CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%. The company had revenue of $13.36 million during the quarter, compared to the consensus estimate of $7.39 million.

About CASI Pharmaceuticals

(Free Report)

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.